Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 485 Million USD | -13.22% |
| 2023 | 558.87 Million USD | 3.0% |
| 2022 | 542.58 Million USD | 10.82% |
| 2021 | 489.58 Million USD | 9.79% |
| 2020 | 445.92 Million USD | 10.7% |
| 2019 | 402.8 Million USD | -17.56% |
| 2018 | 488.62 Million GBP | -4.89% |
| 2017 | 513.73 Million GBP | 3.59% |
| 2016 | 495.95 Million GBP | 46.21% |
| 2015 | 339.2 Million GBP | 13.48% |
| 2014 | 298.9 Million GBP | -3.55% |
| 2013 | 309.9 Million GBP | -1.27% |
| 2012 | 313.9 Million GBP | 15.92% |
| 2011 | 270.8 Million GBP | -6.81% |
| 2010 | 290.6 Million GBP | -0.92% |
| 2009 | 293.3 Million GBP | 16.9% |
| 2008 | 250.9 Million GBP | -11.62% |
| 2007 | 283.9 Million GBP | -9.09% |
| 2006 | 312.3 Million GBP | 485.81% |
| 2005 | 53.31 Million GBP | 15.13% |
| 2004 | 46.3 Million GBP | -14.33% |
| 2003 | 54.05 Million GBP | 16.51% |
| 2002 | 46.39 Million GBP | -16.62% |
| 2001 | 55.63 Million GBP | -6.71% |
| 2000 | 59.63 Million GBP | 283.1% |
| 1999 | 15.56 Million GBP | 38.85% |
| 1998 | 11.21 Million GBP | 21.57% |
| 1997 | 9.22 Million GBP | 6.58% |
| 1996 | 8.65 Million GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 613.18 Million USD | 9.72% |
| 2024 Q3 | 485 Million GBP | -20.79% |
| 2024 Q1 | 481 Million GBP | -13.93% |
| 2024 Q2 | 612.31 Million GBP | 27.3% |
| 2024 Q4 | 485 Million GBP | -0.0% |
| 2023 Q3 | 440.3 Million GBP | -19.84% |
| 2023 Q4 | 558.87 Million USD | 26.93% |
| 2023 Q2 | 549.3 Million USD | 20.94% |
| 2023 FY | 558.87 Million USD | 3.0% |
| 2023 Q1 | 454.2 Million GBP | 1.88% |
| 2022 Q1 | 389.8 Million GBP | -20.38% |
| 2022 Q2 | 389.8 Million GBP | 0.0% |
| 2022 Q3 | 445.8 Million GBP | 14.37% |
| 2022 Q4 | 445.8 Million GBP | 0.0% |
| 2022 FY | 542.58 Million USD | 10.82% |
| 2021 Q3 | 354.4 Million GBP | -24.54% |
| 2021 Q4 | 489.58 Million GBP | 38.15% |
| 2021 Q1 | 343.6 Million GBP | -22.95% |
| 2021 Q2 | 469.68 Million GBP | 36.69% |
| 2021 FY | 489.58 Million USD | 9.79% |
| 2020 FY | 445.92 Million USD | 10.7% |
| 2020 Q1 | 343.9 Million GBP | -16.03% |
| 2020 Q4 | 445.92 Million GBP | 23.56% |
| 2020 Q3 | 360.9 Million GBP | -20.78% |
| 2020 Q2 | 455.58 Million GBP | 32.48% |
| 2019 Q3 | 316.5 Million GBP | 0.67% |
| 2019 FY | 402.8 Million USD | -17.56% |
| 2019 Q1 | 314.4 Million GBP | -15.05% |
| 2019 Q2 | 314.4 Million GBP | 0.0% |
| 2019 Q4 | 409.55 Million GBP | 29.4% |
| 2018 Q1 | 351.8 Million GBP | -11.05% |
| 2018 Q3 | 370.1 Million GBP | 5.2% |
| 2018 Q4 | 370.1 Million GBP | 0.0% |
| 2018 FY | 488.62 Million GBP | -4.89% |
| 2018 Q2 | 351.8 Million GBP | 0.0% |
| 2017 Q4 | 395.5 Million GBP | 0.0% |
| 2017 FY | 513.73 Million GBP | 3.59% |
| 2017 Q3 | 395.5 Million GBP | -4.7% |
| 2017 Q2 | 415 Million GBP | 0.0% |
| 2017 Q1 | 415 Million GBP | 11.86% |
| 2016 Q1 | 357.2 Million GBP | 5.31% |
| 2016 Q3 | 371 Million GBP | 3.86% |
| 2016 Q4 | 371 Million GBP | 0.0% |
| 2016 FY | 495.95 Million GBP | 46.21% |
| 2016 Q2 | 357.2 Million GBP | 0.0% |
| 2015 Q2 | 346.9 Million GBP | 0.0% |
| 2015 Q1 | 346.9 Million GBP | 16.06% |
| 2015 FY | 339.2 Million GBP | 13.48% |
| 2015 Q3 | 339.2 Million GBP | -2.22% |
| 2015 Q4 | 339.2 Million GBP | 0.0% |
| 2014 Q1 | 322.1 Million GBP | 3.94% |
| 2014 FY | 298.9 Million GBP | -3.55% |
| 2014 Q4 | 298.9 Million GBP | 0.0% |
| 2014 Q2 | 322.1 Million GBP | 0.0% |
| 2014 Q3 | 298.9 Million GBP | -7.2% |
| 2013 Q2 | 313.1 Million GBP | 0.0% |
| 2013 Q3 | 309.9 Million GBP | -1.02% |
| 2013 FY | 309.9 Million GBP | -1.27% |
| 2013 Q4 | 309.9 Million GBP | 0.0% |
| 2012 Q2 | 286 Million GBP | 0.0% |
| 2012 FY | 313.9 Million GBP | 15.92% |
| 2012 Q4 | 313.9 Million GBP | 0.0% |
| 2011 Q4 | 270.8 Million GBP | 0.0% |
| 2011 FY | 270.8 Million GBP | -6.81% |
| 2011 Q2 | 283.2 Million GBP | 0.0% |
| 2010 Q4 | 290.6 Million GBP | 0.0% |
| 2010 Q2 | 304 Million GBP | 0.0% |
| 2010 FY | 290.6 Million GBP | -0.92% |
| 2009 Q4 | 293.3 Million GBP | 0.0% |
| 2009 FY | 293.3 Million GBP | 16.9% |
| 2009 Q2 | 320.3 Million GBP | 0.0% |
| 2008 FY | 250.9 Million GBP | -11.62% |
| 2008 Q4 | 250.9 Million GBP | 0.0% |
| 2008 Q2 | 270.7 Million GBP | 0.0% |
| 2007 Q4 | 283.9 Million GBP | 0.0% |
| 2007 Q2 | 296.8 Million GBP | 0.0% |
| 2007 FY | 283.9 Million GBP | -9.09% |
| 2006 Q3 | 215.44 Million GBP | 0.0% |
| 2006 FY | 312.3 Million GBP | 485.81% |
| 2006 Q1 | 47.21 Million GBP | 0.0% |
| 2005 FY | 53.31 Million GBP | 15.13% |
| 2005 Q1 | 50.81 Million GBP | 0.0% |
| 2005 Q3 | 53.31 Million GBP | 0.0% |
| 2004 FY | 46.3 Million GBP | -14.33% |
| 2004 Q3 | 46.3 Million GBP | 0.0% |
| 2004 Q1 | 53.86 Million GBP | 0.0% |
| 2003 FY | 54.05 Million GBP | 16.51% |
| 2002 FY | 46.39 Million GBP | -16.62% |
| 2001 FY | 55.63 Million GBP | -6.71% |
| 2000 FY | 59.63 Million GBP | 283.1% |
| 1999 FY | 15.56 Million GBP | 38.85% |
| 1998 FY | 11.21 Million GBP | 21.57% |
| 1997 FY | 9.22 Million GBP | 6.58% |
| 1996 FY | 8.65 Million GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1767843.717% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -5023.643% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -569.233% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -59865.826% |
| Rebus Holdings, Inc. | 5.24 Million USD | -9152.194% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -721.838% |
| Qrons Inc. | 1.48 Million USD | -32478.476% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -39452.672% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -547.357% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1085008.287% |
| Skye Bioscience, Inc. | 14.07 Million USD | -3346.504% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -809.858% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -4961.562% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -114946.683% |
| SQZ Biotechnologies Company | 50.03 Million USD | -869.244% |
| Intellipharmaceutics International Inc. | 12 Million USD | -3938.716% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -12492.745% |
| Mesoblast Limited | 188.44 Million USD | -157.37% |
| Marizyme, Inc. | 26.67 Million USD | -1718.133% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -8201.069% |
| Pharming Group N.V. | 244.07 Million USD | -98.711% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -24027.793% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -19174.117% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -12663.158% |
| ContraFect Corporation | 32.53 Million USD | -1390.886% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -24378.779% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -12570.967% |
| IMV Inc. | 37.93 Million USD | -1178.577% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -4017.779% |
| MultiCell Technologies, Inc. | 1617.67 USD | -29981292.991% |
| ONE Bio Corp. | 27.49 Million USD | -1663.905% |
| Accustem Sciences Inc. | 1.07 Million USD | -44839.073% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -526.477% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -22830.694% |
| Q BioMed Inc. | 8.13 Million USD | -5863.404% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -484.795% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -9324.732% |
| Biomind Labs Inc. | 1.49 Million USD | -32263.28% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -308.517% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -5263.742% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -2535.38% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -33724.757% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -341220.947% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -241054.359% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -8340.917% |
| GB Sciences, Inc. | 5.41 Million USD | -8852.375% |
| Alpha Cognition Inc. | 7.16 Million USD | -6669.23% |
| HST Global, Inc. | 593.59 Thousand USD | -81605.815% |
| CSL Limited | 18.62 Billion USD | 97.395% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -38416.733% |
| Halberd Corporation | 728.71 Thousand USD | -66455.147% |
| Enzolytics Inc. | 365.26 Million USD | -32.779% |
| Agentix Corp. | 2.51 Million USD | -19218.438% |
| Resverlogix Corp. | 67.39 Million USD | -619.627% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -57725.384% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | -9.001% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -28196.383% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1859.911% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -3974.568% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -13132.696% |
| AVAX Technologies, Inc. | 3.99 Million USD | -12043.99% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1759122.315% |
| Genscript Biotech Corporation | 1.32 Billion USD | 63.42% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -203123.076% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -12887.688% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -71136.16% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -17785.848% |
| Kadimastem Ltd | 3.5 Million USD | -13737.9% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -724548.508% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -864.905% |
| BioStem Technologies, Inc. | 15.9 Million USD | -2949.419% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -104268.634% |
| LadRx Corporation | 2.2 Million USD | -21940.165% |
| Cell Source, Inc. | 15.8 Million USD | -2968.316% |
| Regen BioPharma, Inc. | 5.45 Million USD | -8786.664% |
| Regen BioPharma, Inc. | 5.45 Million USD | -8786.664% |
| NovAccess Global Inc. | 7.86 Million USD | -6069.909% |
| Affymax, Inc. | 8.87 Million USD | -5367.253% |
| Itoco Inc. | 1.65 Million USD | -29237.913% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -23540.489% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -7917.854% |
| Mobile Lads Corp. | 1.31 Million USD | -36824.333% |
| CytoDyn Inc. | 127.89 Million USD | -279.22% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1160214.84% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -30863.172% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -4291.012% |
| SYBLEU INC | 681.41 Thousand USD | -71075.631% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -7848.337% |
| International Stem Cell Corporation | 5.27 Million USD | -9090.828% |
| Bioxytran, Inc. | 3.24 Million USD | -14825.373% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -77399.684% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -10404.372% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -1083.042% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -2078.307% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -23846.041% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -8753.596% |
| Neutra Corp. | 973.52 Thousand USD | -49718.752% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1571.549% |
| PureTech Health plc | 125.58 Million USD | -286.199% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -12808.807% |
| IXICO plc | 1.9 Million USD | -25422.393% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -2262.512% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -369.397% |
| CSL Limited | 18.62 Billion USD | 97.395% |
| Cellectis S.A. | 249.36 Million USD | -94.491% |